Long-Term PPI Use in Insurance Claims
Manage proton pump inhibitor risks and optimize gastric protection
Published: 3 April 2026 | Updated: 3 April 2026
PPI Use in Claims: Necessary but Risky Long-Term
Proton pump inhibitors (PPIs) are essential gastroprotective agents in personal injury claims, particularly when claimants require NSAIDs or antiplatelet therapies. However, PPI use frequently extends far beyond recommended duration. A claimant initially prescribed omeprazole for NSAID-related dyspepsia often continues indefinitely, sometimes for years after the NSAID has ceased. Long-term PPI use carries significant risks: hypomagnesemia, vitamin B12 deficiency, osteoporosis, increased fracture risk, altered gut microbiome, and possibly elevated infection risk. As an insurer, your challenge is balancing genuine need for gastroprotection against long-term medication risks that may ultimately exceed the benefit. This article equips you to identify appropriate PPI duration, recognize when deprescribing is warranted, and implement monitoring that protects claimant safety.
PPI Pharmacology and Appropriate Use
Proton pump inhibitors irreversibly inhibit the hydrogen potassium ATPase pump in gastric parietal cells, suppressing gastric acid secretion by up to 99 percent. This is effective at preventing ulceration and managing reflux. Common agents include omeprazole, esomeprazole, lansoprazole, and pantoprazole. Standard doses are omeprazole 20mg daily, esomeprazole 20mg daily, and equivalent doses of others.
Recommended Duration
- Acute peptic ulcer treatment: 4 to 8 weeks
- NSAID gastroprotection during active NSAID use: Duration of NSAID therapy
- GERD (non-erosive): 4 to 8 weeks; longer only if symptoms persist
- Chronic GERD or Barrett's esophagus: Long-term use may be justified, but requires periodic reassessment
- Post-ulcer maintenance: 6 to 12 months after healing, then consider cessation
Risks of Long-Term PPI Use
Hypomagnesemia
PPIs reduce gastric acid, impairing magnesium absorption. Chronic use leads to hypomagnesemia in 13 to 25 percent of users. Symptoms include weakness, muscle cramping, arrhythmias, and personality changes. Severe hypomagnesemia causes tetany or seizures. In claims with multiple medications, hypomagnesemia can be overlooked, attributed to other causes. Regular monitoring is essential.
Vitamin B12 Deficiency
Gastric acid is necessary for vitamin B12 absorption. PPIs reduce acid, leading to B12 deficiency in 2 to 5 percent of long-term users. B12 deficiency causes neuropathy, anemia, and cognitive symptoms. In claims where a claimant reports fatigue, neuropathy, or cognitive changes, PPI-induced B12 deficiency should be considered.
Osteoporosis and Fracture Risk
PPIs impair calcium absorption and may alter bone remodeling. Long-term use associates with increased hip and spine fracture risk, particularly in women and older adults. In claims with mobility goals or return-to-work requiring safe movement, PPI-induced osteoporosis is a complication to prevent.
Alterations to Gut Microbiome
PPIs reduce gastric acid, leading to bacterial overgrowth and altered colonic flora. This associates with increased risk of Clostridioides difficile infection and possibly small intestinal bacterial overgrowth (SIBO). Some claimants on long-term PPIs report persistent diarrhea or constipation; dysbiosis may contribute.
Acute Kidney Injury
Rare but serious: some cases of acute interstitial nephritis associate with PPI use. Chronic kidney disease may accelerate on PPIs. Claimants with baseline renal impairment require careful monitoring.
Risk Stratification for Long-Term PPI Use
| Risk Factor | Impact | Monitoring Recommendation |
|---|---|---|
| PPI use beyond 12 months | Cumulative risk of deficiencies and bone loss | Assess ongoing indication; consider deprescribing trial |
| Age over 65 | Increased fracture risk from osteoporosis; B12 absorption already declining | Baseline bone density; annual magnesium and B12; higher deprescribing priority |
| Concurrent bisphosphonate or calcium supplementation | PPI may reduce bisphosphonate or calcium efficacy | Monitor bone density; ensure adequate separation of PPI and these agents |
| Renal impairment (eGFR under 60) | Acute kidney injury risk; electrolyte imbalances more likely | Regular renal function monitoring; lower deprescribing threshold |
| History of Clostridium difficile infection | Increased recurrence risk | Strong candidate for deprescribing; monitor for signs of recurrence |
| No documented GERD or ulcer history; PPI initiated for dyspepsia only | Likely unnecessary long-term; risk exceeds benefit | Strongly consider deprescribing |
Monitoring Protocol for Long-Term PPI Users
PPI Monitoring Schedule
Baseline (before or at initiation): Magnesium, vitamin B12, calcium, vitamin D, baseline renal function, bone density (DXA) if age over 65 or risk factors.
At 12 weeks: Clinical reassessment. Is indication for PPI ongoing? Any signs of GERD, reflux, or dyspepsia if PPI were ceased? Side effects or tolerability issues?
At 6 months: If continuing long-term, repeat magnesium and B12. Assess for symptoms of deficiency: fatigue, paresthesia, cognitive changes.
Annually: Repeat magnesium, B12, calcium, vitamin D. If age over 65, repeat bone density every 2 years. Renal function if baseline impairment.
At any time after 12 months: Reassess indication. Attempt deprescribing trial if gastroprotection no longer clearly necessary.
Management of Detected Deficiencies
- Hypomagnesemia: Magnesium supplementation (typically magnesium oxide 400 to 500mg daily) and consideration of PPI deprescribing. Some sources suggest separating PPI and magnesium supplements by 2 hours.
- Vitamin B12 deficiency: B12 supplementation (oral cyanocobalamin 1000 to 2000 mcg daily or parenteral injections monthly) and PPI deprescribing if possible. Monitor for pernicious anemia.
- Osteoporosis: Calcium and vitamin D supplementation; consider bisphosphonates if fracture risk high. Deprescribe PPI if possible to improve bone remodeling.
Deprescribing Long-Term PPIs
Many claimants can cease PPIs safely, particularly if gastroprotection was initiated for temporary reasons (NSAID use, acute ulcer) that no longer apply. Some rebound acid hypersecretion occurs initially after cessation but resolves within 1 to 2 weeks. Deprescribing should be planned and monitored.
PPI Deprescribing Strategy
Week 1: Assess continued indication. Document whether GERD, ulcer disease, or gastroprotection is still necessary. Clarify with claimant and prescriber whether PPI can safely cease.
Week 2: Implement dietary and lifestyle modifications. Reduce acidic foods, spicy foods, late meals, alcohol. Elevate head of bed if reflux. Start stress management if applicable.
Week 3: Reduce PPI dose by 50 percent. If on omeprazole 20mg daily, reduce to 10mg (or switch to alternate-day dosing). Continue dietary modifications.
Week 4-6: Continue reduced dose or alternate-day dosing. Monitor for rebound reflux or dyspepsia. Expect mild acid rebound for 1 to 2 weeks; reassure claimant this is temporary.
Week 7: Cease PPI completely. Continue dietary and lifestyle modifications. Most claimants stabilize within 2 weeks post-cessation.
When Deprescribing May Not Be Appropriate
- Documented GERD with erosive disease or Barrett's esophagus: Long-term PPI often continues indefinitely
- Chronic NSAID use for ongoing pain: PPI should continue as long as NSAID continues
- Chronic anticoagulation or antiplatelet therapy: PPI may continue for gastroprotection duration of anticoagulation
- History of severe peptic ulcer with complications: Maintenance PPI may prevent recurrence
Alternatives to Long-Term PPIs
For claimants with mild or intermittent GERD, consider alternatives to chronic PPI therapy:
- Dietary modification: Avoid acidic, spicy, fatty foods; small meals; avoid eating close to bedtime
- H2 receptor antagonists: Ranitidine (if available) or famotidine for intermittent reflux; less suppressive than PPIs, lower risk profile
- Antacids or alginates: For acute symptomatic relief without long-term systemic effects
- Weight optimization: Weight loss reduces GERD symptoms
Insurer Governance: PPI Protocol
- Initial prescription: Approve for documented indication (GERD, ulcer, NSAID gastroprotection). Request documented indication at initiation.
- At 12 weeks: Request reassessment confirming ongoing indication and plan for continuation vs. cessation.
- Beyond 12 months: Mandatory baseline labs: magnesium, B12, calcium, vitamin D, and renal function. No PPI continuation without documented indication and lab reassessment.
- Age over 65 or risk factors: Bone density assessment baseline; annual labs including magnesium and B12.
- Every 6 to 12 months: Reassess indication. Support deprescribing trial if gastroprotection no longer necessary.
- Concurrent NSAID or anticoagulation: Continue PPI for duration of concurrent agent; reassess when those medications cease.
Is your claimant on long-term PPI without recent indication assessment or monitoring?
IMM's medication reviews assess PPI appropriateness, ensure adequate monitoring for deficiencies, and guide safe deprescribing when gastroprotection is no longer necessary. We work with your claims team to optimize gastric protection while minimizing long-term medication risks and costs.
Request a Medication Review
